when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

222 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT920 Endpoints708 BioPharma Dive269 onclive165 BioSpace155 Fierce Biotech147 globenewswire health73 raps

therapy area

all Oncology5411 Rare Disease1113 Cardiology987 Hematology871 Immunology833 Pulmonology704 Psychiatry & CNS

Austria launches up to €100 million anchor investment for growth fund, aiming to channel half‑billion euros into biotech
Austria's government announced a new national Startup & Scaleup Fund as part of the 2027/2028 budget, with an anchor investment of up to €100 million. The public money is designed to attract priva…
BioSpace · 3h agoPositive↗ source
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
Biotech companies don’t hide or obfuscate strong data.
STAT · 2h ago↗ source
Global Ebola preparedness fixated on one strain, leaving gaps for other species

← prev

page 1 of 9

55

643

Endocrinology & Metabolism320

Ophthalmology313

Infectious Disease300

Krutika Kuppalli, a former WHO medical officer, and virologist Placide Mbala write that the world’s readiness for Ebola has been narrowly focused. They draw on Kuppalli’s experience in the 2014‑201…

STAT · 1d agoNegative↗ source

AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purification

The industry is moving from ex vivo to in vivo gene delivery, a change that forces viral vector manufacturers to rethink scale, purity, cell lines and analytical methods. In in vivo approaches the…

BioSpace · 1d agoPositive↗ source

CLINUVEL to cut up to 20% of staff and move headquarters to New York

CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…

BioSpace · 19h agoLayoffsNegative↗ source

FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cuts

The U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…

STAT · 4d agoApprovalPositive↗ source

LifeMine Therapeutics secures $263 million in dual venture rounds to advance organ transplant aftercare drug

LifeMine Therapeutics announced it has raised a total of $263 million through a $75 million Series D and an $188 million Series F round, opting for private financing rather than an IPO. The capita…

BioSpace · 4d agoDealPositive↗ source

Sanofi pauses Phase 2 bronchiectasis study of SAR445399 amid new CEO’s portfolio review

Sanofi has halted a Phase 2 trial of its investigational antibody SAR445399 in non‑cystic fibrosis bronchiectasis. The pause was attributed to strategic business reasons linked to an internal portf…

BioSpace · 4d agoRegulatoryNeutral↗ source

U.S. experts to evaluate if measles elimination status still holds amid rising cases

Noel T. Brewer, chair of the U.S. National Verification Committee, explains that his group will review the CDC’s annual measles report to decide if the United States continues to meet elimination c…

STAT · 5d agoNegative↗ source

Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debut

Attovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…

Endpoints · 5d agoDealPositive↗ source

Analysts spot several biotech firms as likely M&A targets amid rising pharma deal activity

Pharma companies are actively looking for acquisition opportunities, and analysts have identified a handful of biotech firms that could be next in line for buyouts. Recent transactions have center…

BioSpace · 6d agoDealNeutral↗ source

Amgen drops Phase 1 obesity drug AMG 513, leaving MariTide as its only weight-loss candidate and eyes early-stage deals

Amgen announced it is halting development of AMG 513, a Phase 1 obesity therapy, leaving MariTide as its sole weight‑loss asset. The company said its late‑stage pipeline is largely full, so future…

BioSpace · 5d agoDealNeutral↗ source

Novo Nordisk CEO says innovation is essential as pipeline faces setbacks

During Novo Nordisk's second-quarter earnings call, CEO Maziar Mike Doustdar said that failure is a normal part of drug development and emphasized that the company's survival depends on continual i…

BioSpace · 5d agoEarningsNeutral↗ source

Only one third of US prostate cancer patients received pre-biopsy MRI in 2022, far below Western norms

MRI is considered the standard pre-biopsy imaging tool for prostate cancer in most western nations, yet a new analysis shows that only about a third of US cases used it in 2022. In the United Stat…

STAT · 6d agoNegative↗ source

Five BioSpace NextGen companies debut on US markets in 2026, four actively hiring

BioSpace NextGen honorees accounted for about one third of the 14 U.S. biotech companies that went public in 2026. The five companies together raised roughly $1.5 billion in IPO proceeds, includin…

BioSpace · 6d agoPositive↗ source

Moderna begins early-stage trial of mRNA Ebola vaccine

Moderna announced the launch of an early-phase clinical trial testing an mRNA vaccine designed to protect against Ebola virus. The study will enroll healthy volunteers to evaluate the vaccine's saf…

STAT · 5d agoNeutral↗ source

Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativa

Merck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…

BioSpace · 6d agoNegative readoutNeutral↗ source

Novo Nordisk’s Phase 3 failure of IL-6 drug ziltivekimab rattles inflammation-focused pipeline

Novo Nordisk reported that its late-stage IL-6 inhibitor ziltivekimab did not achieve its primary goal in the Phase 3 ZEUS trial, which was designed to lower cardiovascular complications. The disa…

BioSpace · 7d agoNegative readoutNegative↗ source

BioNTech appoints Sobi CEO Guido Oelkers as new chief, founders to launch separate mRNA biotech

BioNTech announced that Guido Oelkers, current chief executive of Swedish Orphan Biovitrum (Sobi), will assume the role of CEO in early 2027. The move follows the earlier decision of co‑founders U…

BioSpace · 7d agoNeutral↗ source

AbbVie says Skyrizi maintains strong sales momentum as competition rises

AbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…

Endpoints · 10d agoPositive↗ source

AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectations

AbbVie’s stock fell about 4% on Friday after the company reported second‑quarter results that modestly exceeded analyst forecasts, disappointing investors who had set very high expectations. The f…

BioSpace · 10d agoEarningsNegative↗ source

BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian data

BMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…

BioSpace · 11d agoEarningsNeutral↗ source

Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programs

Sanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter. The bulk of the charge stems from the decision to terminate development of an eczema trea…

Endpoints · 12d agoNegative↗ source

J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58B

Johnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…

BioSpace · 11d agoDealNeutral↗ source

Pfizer reports Phase 3 success for Litfulo in vitiligo trials; Braveheart and Attovia target $275M and $182M IPOs

Pfizer announced that its experimental drug Litfulo achieved Phase 3 success in two separate studies targeting active and stable nonsegmental vitiligo, an autoimmune condition that causes loss of s…

Endpoints · 11d agoPositive readoutPositive↗ source